Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial

• 主要な著者: Bhagirath B. Solanki (著者), Christine Juergens (著者), Manojkumar B. Chopada (著者), Pravin Supe (著者), Vani Sundaraiyer (著者), Natacha Le Dren-Narayanin (著者), Mark W. Cutler (著者), William C. Gruber (著者), Daniel A. Scott (著者), Beate Schmoele-Thoma (著者)
• フォーマット: 図書
• 出版事項: Taylor & Francis Group, 2017-09-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the ability to enhance immunity (immunologic memory) o...